Lysine residue at position 22 of the AID protein regulates its class switch activity.

Geisberger R, Huemer M, Gassner FJ, Zaborsky N, Egle A, Greil R. PLoS One. 2012,7(2):e30667. doi: 10.1371/journal.pone.0030667. Epub 2012 Feb 20.

Canonical and noncanonical Hedgehog/GLI signaling in hematological malignancies.

Aberger F, Kern D, Greil R, Hartmann TN. Vitam Horm. 2012,88:25-54. doi: 10.1016/B978-0-12-394622-5.00002-X.

Actinomycin D induces p53-independent cell death and prolongs survival in high-risk chronic lymphocytic leukemia.

Merkel O, Wacht N, Sifft E, Melchardt T, Hamacher F, Kocher T, Denk U, Hofbauer JP, Egle A, Scheideler M, Schlederer M, Steurer M, Kenner L, Greil R. Leukemia. 2012 Dec,26(12):2508-16. doi: 10.1038/leu.2012.147. Epub 2012 Jun 1.

Sentinel node biopsy after primary chemotherapy in breast cancer: a note of caution from results of ABCSG-14.

Tausch C, Steger GG, Haid A, Jakesz R, Fridrik MA, Reitsamer R, Pöstlberger S, Lang A, Gnant M, Greil R. Breast J. 2011 May-Jun,17(3):230-8. doi: 10.1111/j.1524-4741.2011.01073.x. Epub 2011 Mar 31.

Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools.

Merkel O, Hamacher F, Sifft E, Kenner L, Greil R Mol Cancer Ther. 2011 Jul,10(7):1127-36. doi: 10.1158/1535-7163.MCT-11-0042. Epub 2011 Jun 28. Review.

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Lancet. 2011 Aug 27,378(9793):771-84. doi: 10.1016/S0140-6736(11)60993-8. Epub 2011 Jul 28.

A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors.

Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Müller V, Jänicke F, Schmidt M, Kölbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, et al. PLoS One. 2011,6(8):e23758. doi: 10.1371/journal.pone.0023758. Epub 2011 Aug 18

Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin’s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group.

Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, Eich HT, Mueller-Hermelink HK, Kanz L, Greil R, Rank A, Paulus U, Smardova L, Huber C, Dörken B, Nerl C, Krause SW, Mueller RP, Fuchs M, Engert A. J Clin Oncol. 2011 Nov 10,29(32):4234-42. doi: 10.1200/JCO.2010.33.9549. Epub 2011 Oct 11.

Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.

Bago-Horvath Z, Rudas M, Dubsky P, Jakesz R, Singer CF, Kemmerling R, Greil R, Jelen A, Böhm G, Jasarevic Z, Haid A, Gruber C, Pöstlberger S, Filipits M, Gnant M Clin Cancer Res. 2011 Dec 15,17(24):7828-34. doi: 10.1158/1078-0432.CCR-11-1846. Epub 2011 Oct 13.

Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.

Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. Lancet. 2011 Nov 12,378(9804):1707-16. doi: 10.1016/S0140-6736(11)61629-2. Epub 2011 Oct 19. Review.